WHAT AND WHY? HOW AND WITH WHOM? RESULTS, IMPACT AND RECOMMENDATIONS What next? Needle-free diabetes management Fast interstitial fluid sampling for non-invasive diabetes management Dr. Alejandro García Pérez, PhD. • Over 400 MILLION people suffer from diabetes. • Over 1.9 BILLION people are overweight (at risk of getting diabetes). • Our technology promotes better management and prevention of diabetes by enabling convenient, non-invasive and painless glucose monitoring. We developed a patent pending solution to extract interstitial fluid from the dermis in a painless and non-invasive manner. The concentration of glucose in interstitial fluid is measured using state-of-the-art biosensors, and it correlates with blood glucose. Key collaborators and stakeholders: University of Helsinki, Åbo Akademi University, Business Finland, and IoT Forge Foundation. The project involved top experts from Finland, México, Russia and Canada. Results from a pilot study in healthy individuals showed that our technology meets the level of analytical accuracy required for regulatory clearance. This project has created a compelling foundation to establish GlucoModicum Oy (Y-tunnus: 2900506-7). Public Relations & Eco-system engagement with high impact audiences. Finalize the prototype Start early-phase clinical trials Apply for regulatory clearance Continue engagement with technology and pharma companies • Patent pending technology for extraction of dermal interstitial fluid is tested in humans. • Initial prototype built. We demonstrated that the solution can be implemented into a small formfactor. • Final solution encompasses our novel interstitial fluid sampling method, state-of-the-art biosensors and a convenient user interface. Figure 1. Key achievements More information: Alejandro García Pérez [email protected] Partners: From academic research to scientific and societal impact